ATV041, an orally active compound that combines features of Ibuprofen and nucleotide analogues, enhances the oral pharmacokinetic (PK) profile and tissue distribution, exhibiting anti-mouse hepatitis virus (MHV) activity. The compound demonstrates a dose-dependent reduction in viral load, tissue damage, and virus-induced inflammation [1].

The chemical compound ATV041 exhibits inhibitory activity against CCoV, FIPV, and TGEV with EC50 values of 1.406 µM, 7.34 µM, and 3.777 µM, respectively [1].

ATV041 (200 mg/kg; oral; single dose) distributes extensively and rapidly throughout the plasma, liver, lungs, and kidney tissues [1]. When administered orally in single doses of 10, 50, and 200 mg/kg, ATV041 inhibits viral replication in the liver and lungs in a dose-dependent manner. Additionally, ATV041 decreases the expression of inflammatory cytokines TNF-α, IL-1β, IL-6, IFN-γ, and CXCL10, leading to amelioration of tissue damage [1].